Regeneron Pharmaceuticals IncREGNannounced early data for ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer (NSCLC).
Within 42 patients who received full doses of ubamatamab, a 14% (6 of 42 patients) overall response rate (ORR) was achieved across dose levels.
The ORR increased to 21% in those without visceral metastases and 31% in those with high MUC16-expressing tumors.
Across dose levels, the disease control rate was 57%, and the median duration of response was 12 months.
Preliminary first-in-human results for REGN5093 were also published in an ESMO scientific abstract, with updated data and additional response rates.
Among 36 patients with MET-altered advanced NSCLC who received the highest dose tested to date, 6 experienced a partial response, with 5 of these responses occurring in patients who had received prior anti-PD-1 treatment.
No dose-limiting toxicities or treatment-related deaths have been observed as of the data cutoff.
Price Action: REGN shares closed higher by 2.18% at $724.32 on Friday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
